CN-122003275-A - Cough treatment device

CN122003275ACN 122003275 ACN122003275 ACN 122003275ACN-122003275-A

Abstract

A cough treating device is characterized by comprising a light source for emitting light and a light irradiation probe for irradiating the light, wherein the light emitted by the light source is irradiated from the light irradiation probe to the vagus nerve of the neck of a patient and the vicinity thereof transdermally, and the excessive hyperthermia of the vagus nerve in the vicinity of the respiratory tract which is the cause of cough is directly inhibited, thereby realizing a safe and effective treatment method with little side effects instead of the drug therapy which causes the whole body symptoms.

Inventors

South stripe
A Book
Kawa yuu
Ishiya Naoya

Assignees

帝人制药株式会社

Dates

Publication Date: 20260508
Application Date: 20241010
Priority Date: 20231013

Claims (4)

1. The cough therapeutic device is characterized by comprising a light source for emitting light and a light irradiation probe for irradiating the light, and the light emitted by the light source is irradiated from the light irradiation probe to the vagus nerve of the neck of the patient and the vicinity thereof through skin.
2. The cough therapeutic device of claim 1, wherein the light irradiation probe is a device that irradiates light to a lower ganglion, an upper ganglion, a pharyngeal branch, or an upper laryngeal nerve in the cervical vagus nerve.
3. The cough therapeutic device according to claim 1, wherein the light irradiation probe is a device that irradiates light to a region behind a mandibular angle or below mastoid of the neck of the patient.
4. The cough therapeutic apparatus according to claim 1, wherein an average power of the light irradiated from the light irradiation probe is 200mW to 8w, an average power density obtained by dividing the average power of the light irradiated from the light irradiation probe by an irradiation area of the light is 250mW/cm 2 or more to 10,000mW/cm 2 , an energy of the light amount irradiated from the light irradiation probe is 60J to 4,800J per treatment, an energy density obtained by dividing the energy of the light amount of the light irradiated from the light irradiation probe by the irradiation area of the light is 75J/cm 2 ~6,000J/cm 2 per treatment, and a wavelength of the light irradiated from the light irradiation probe is 700nm to 900nm.

Description

Cough treatment device Technical Field The present invention relates to a cough treatment apparatus for treating cough by irradiating vagus nerve with light. Background Cough is originally a biological defensive response that is used to exclude secretions or foreign matter residing in the respiratory tract from the respiratory tract. Cough is classified into acute cough less than 3 weeks, prolonged cough more than 3 weeks and less than 8 weeks, and chronic cough more than 8 weeks based on the duration of cough. The most common cause of acute cough is viral common cold, but most patients can recover as long as the disease is treated. Prolonged or chronic cough is classified into dry cough without expectoration and wet cough with expectoration according to the presence or absence of expectoration, and most of the cough is dry cough, and cough itself is the subject of treatment. It should be noted that wet cough is caused by excessive secretion of mucus in the respiratory tract. Cough lasting for 8 weeks or more is called chronic cough, and the prevalence in japan is said to be about 2 to 4% (about 250 to 500 tens of thousands of people). The diagnosis and treatment of chronic cough are carried out according to the flow of guidelines, and most of them are effective after treatment by various causes of diseases according to the cause, such as cough asthma, allergic cough, gastroesophageal reflux disease, post-infection cough, and sinus bronchosyndrome. However, there are refractory cases that do not work even when the causative disease is treated. It is said that in chronic cough-treated patients in japan, there are about 20% (about 20-40 ten thousand people) refractory cases of chronic cough. In recent years, CHS (cough hypersensitivity syndrome: cough hypersensitive syndrome) has been proposed as a concept for explaining the common pathological condition of treatment-resistant cough irrespective of the presence or absence of causative disease, and chronic cough with difficulty in treatment has been attracting attention. As a therapeutic agent for cough, a central antitussive containing codeine or dihydrocodeine is sometimes used. Recently, a selective P2X3 receptor antagonist (gefarabine citrate) has been approved in japan as a therapeutic agent for intractable chronic cough. However, in cough treatment using therapeutic agents, side effects due to systemic actions such as constipation, nausea, vomiting, dizziness, and dysgeusia have been reported (non-patent document 1), and development of new drugs with reduced side effects has been underway (patent document 1). LLLT (Low LEVEL LASER THERAPY: low-power laser therapy), one of phototherapy, has been studied as a physical therapy method for anti-inflammatory action or suppressing excessive nerve growth, and has been used for various diseases such as overactive bladder, irritable bowel syndrome, chronic pain, and facial neuralgia (patent document 2). Prior art literature Patent literature Patent document 1, japanese patent application 6725188, Patent document 2, WO 2022/019293. Non-patent literature Non-patent document 1, lyfnua tablet 45mg instruction (MSD/apricot forest). Disclosure of Invention Problems to be solved by the invention Chronic cough is not a disease related to death, but chronic cough causes a decrease in both public and private manifestations, resulting in a decrease in QOL of the patient. As described above, although there are therapeutic agents, there is a problem of side effects, and the conventional therapeutic or prophylactic effects cannot be said to be sufficient. In view of the above background, new treatments or preventative methods for chronic cough are desired. The selective P2X3 receptor antagonist developed as a therapeutic agent for chronic cough with difficulty or unknown cause is a substance that inhibits extracellular ATP from binding to Adenosine Triphosphate (ATP) receptor expressed on C fibers of the respiratory vagus nerve, and can inhibit cough caused by inflammation of the respiratory tract. The P2X3 receptor is specifically expressed on C fibers as afferent nerves (sensory nerves), and densely distributed in viscera, skin, joints, and the like. Therefore, administration of such a therapeutic agent as an oral preparation inhibits the P2X3 receptor in the whole body other than the respiratory tract, and causes side effects. The present invention provides a cough treatment device which directly suppresses excessive hyperactivity of the vagus nerve in the vicinity of the respiratory tract, which is a cause of cough, thereby realizing a safe and effective treatment method with little side effects, instead of a drug therapy causing systemic symptoms. Means for solving the problems The present invention provides a phototherapy device for suppressing cough by irradiating a vagus nerve with light such as low-power laser light as shown below. (1) The cough therapeutic device is characterized by comprising a light source for emitt